Gritstone Oncology Inc. (GRTS) Announces Private Placement Financing of $55 Million of Common Stock
- Dollar dishes the pain as selloff rumbles on
- Apple (AAPL) Extends Decline as BofA Downgrades to Neutral on More Balanced Risk/Reward
- Bernstein's Top Indicator Triggers a Buy Signal, Suggests Short-term Tactical Bounce
- This Top Market Analyst Says S&P 500's Ceiling May Be at 3900
- Oil rises towards $90 as OPEC+ considers output cut
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies and vaccines, today announced a $55.0 million private investment in public equity (PIPE) financing from the sale of 5,000,000 shares of its common stock at a price per share of $11.00. Gross proceeds from the PIPE financings total $55.0 million, before deducting placement agent fees and offering expenses. The PIPE is being led by Frazier Life Sciences Public Fund, with additional participation from Redmile Group and Gilead Sciences.
“As long-term backers of Gritstone, we continue to be impressed by the company’s progress and emergence as a leader in development of next generation immunotherapies and vaccines for cancer and infectious diseases,” said Jamie Brush, M.D., General Partner and Portfolio Manager of the Frazier Life Sciences Public Fund. “We believe Gritstone’s EDGE™ platform and integrated vaccine manufacturing capabilities uniquely position the company to rapidly expand into infectious disease vaccine development with a potentially refrigerator stable self-amplifying mRNA vaccine platform. This financing will help ensure Gritstone has the resources to move quickly in this exciting new area, and we are excited to support the company in its next phase of growth.”
The closing of the PIPE financing is subject to customary closing conditions and is expected to close by September 17, 2021. Cowen served as the sole placement agent for the PIPE financing.
The securities sold in this private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the U.S. except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Gritstone bio has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in this private placement.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo Starts Coinbase (COIN) at Underweight, Sees 15% Downside Risk
- BiondVax Pharma (BVXV) Announces Proposed Share Offering, Size not Disclosed
- ZyVersa and Larkspur Health Acquisition (LSPR) Provide Merger, Interim Financing and PIPE Investment Update
Create E-mail Alert Related CategoriesCorporate News, Equity Offerings
Related EntitiesCowen & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!